Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

The Lancet Neurology

Volumn 9, Issue 4, 2010, Pages 381-390

  Wynn, Daniel ^a   Kaufman, Michael ^b   Montalban, Xavier ^c   Vollmer, Timothy ^d   Simon, Jack ^e   Elkins, Jacob ^f   O'Neill, Gilmore ^f   Neyer, Lauri ^g   Sheridan, James ^g   Wang, Chungchi ^g   Fong, Alice ^g   Rose, John W ^h  

^a Carolinas Medical Center ^*

^b CAROLINAS MEDICAL CENTER   (United States)

^c Hospital Universitari Vall d'Hebron   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f BIOGEN   (United States)

^g Facet Biotech   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; DACLIZUMAB; GADOLINIUM; INTERFERON BETA SERINE; PLACEBO;

ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; BACKACHE; BRAIN DAMAGE; CANADA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GERMANY; HEADACHE; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; ITALY; LOW DRUG DOSE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NATURAL KILLER CELL; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SPAIN; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77949301468     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70033-8     Document Type: Article

References (27)

1. Morris J.C., and Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59 suppl 1 (2000) i109-i114
2. Rose J.W., Watt H.E., White A.T., and Carlson N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56 (2004) 864-867
3. Alcina A., Fedetz M., Ndagire D., et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS One 4 (2009) e4137
4. Maier L.M., Lowe C.E., Cooper J., et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 5 (2009) e1000322
5. Hafler D.A., Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 (2007) 851-862
6. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 131 (2008) 3118-3131
7. International Multiple Sclerosis Genetics Consortium. Refining genetic associations in multiple sclerosis. Lancet Neurol 7 (2008) 567-569
8. Kircher B., Latzer K., Gastl G., and Nachbaur D. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 134 (2003) 426-430
9. Van Assche G., Dalle I., Noman M., et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 98 (2003) 369-376
10. Krueger J.G., Walters I.B., Miyazawa M., et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43 (2000) 448-458
11. McDyer J.F., Li Z., John S., Yu X., Wu C.Y., and Ragheb J.A. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 169 (2002) 2736-2746
12. Bielekova B., Catalfamo M., Reichert-Scrivner S., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103 (2006) 5941-5946
13. Airas L., Saraste M., Rinta S., Elovaara I., Huang Y.H., and Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 151 (2008) 235-243
14. Rose J.W., Burns J.B., Bjorklund J., Klein J., Watt H.E., and Carlson N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69 (2007) 785-789
15. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101 (2004) 8705-8708
16. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
17. Cancer therapy evaluation program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed Jan 20, 2009).
18. Kappos L., Clanet M., Sandberg-Wollheim M., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40-47
19. Rossman H.S. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm 10 3 suppl B (2004) S12-S19
20. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289 (2004) 1-16
21. US Department of Health and Human Services. K013169; Cylex immune cell function assay (April 2, 2002). http://www.accessdata.fda.gov/cdrh_docs/pdf/K013169.pdf (accessed Jan 20, 2009).
22. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
23. Miller D.H., Khan O.A., Sheremata W.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 (2003) 15-23
24. low cells. Brain 131 (2008) 1701-1711
25. bright NK cells. Neurology 70 (2008) A376
26. Oh U., Blevins G., Griffith C., et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 66 (2009) 471-479
27. Bielekova B., Howard T., Packer A.N., et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66 (2009) 483-489